PDIA3 and hepatocellular carcinoma: Higher expression of PDIA3 associates with poor survival outcomes in patients with multiple cancers, such as in diffuse gliomas (18), clear cell renal cell carcinoma (19), and hepatocellular carcinoma (HCC) (20).